Journey Medical (DERM) Investor presentation summary

Market position and financial overview

• Commercial-stage pharmaceutical company focused on proprietary and patented dermatology products, targeting a $5.8 billion prescription market including acne, rosacea, and hyperhidrosis.

• 2025 net product revenues reached $61 million with adjusted EBITDA of $2.9 million.

• Market capitalization stands at $142 million with 27.3 million shares outstanding as of May 2026.

• Solid balance sheet with $24.1 million in cash at year-end 2025.

• Stock added to the Russell 2000 and 3000 indexes in June 2025.

Leadership and commercial capabilities

• Senior management team has decades of experience in dermatology and pharmaceutical commercialization.

• Leadership previously launched brands generating over $2 billion in sales and managed product life cycles for extended revenue.

• Sales force averages 9 years of dermatology experience, with 280 years combined, and covers 80% of the top 50 U.S. MSAs.

• Sales representatives are incentivized through equity rewards and entrepreneurial programs.

Product portfolio and growth drivers

• Five core dermatology brands, with Emrosi® as the key growth driver launched in April 2025.

• Emrosi® targets inflammatory lesions of rosacea, with FDA approval in November 2024 and demonstrated head-to-head superiority over Oracea®.

• Other brands include Qbrexza for hyperhidrosis, Amzeeq and Fzilxi for acne and rosacea, and Accutane for severe acne.